Skip to main content
Premium Trial:

Request an Annual Quote

UCSD and TCAG Announce Pharmacogenomic Collaboration

NEW YORK, Sept. 26 (GenomeWeb News) - The University of California, San Diego and the Center for the Advancement of Genomics announced yesterday that they will be formally collaborating to use large-scale genome analysis to predict the occurrence and outcome of disease, with an initial focus on hypertension and cardiovascular disease.


In the hypertension study, UCSD will obtain DNA from a group of patients, then send it to TCAG for sequencing and SNP analysis. While TCAG conducts the sequencing, UCSD researchers will simultaneously run phenotyping tests.


UCSD actually began the hypertension study two years ago with a $2.9 million, four-year grant from the National Heart, Lung and Blood Institute as part of the NIH Pharmacogenomics network. Preliminary results will be announced next month at the Society for Human Genetics meeting in San Francisco.


UCSD's agreement with TCAG is detailed in a multi-year Memorandum of Understanding


The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.